Lipid accumulation in the kidney is a marker of tissue damage and may play a role in the development of renal injury. We have previously shown that long-term administration of angiotensin II in rats causes increased expression of transforming growth factor-b1, coupled with an accumulation of lipids in the tubular and vascular wall cells in the kidney. In this study, we examine the regulation of expression of platelet-derived growth factor (PDGF) and its receptor system and their co-localization with lipid deposits in the kidneys of angiotensin IIinfused rats. Real-time RT-PCR showed that expression of PDGF-B, PDGF-D, and PDGF receptor-b (PDGFR-b) mRNA was increased by angiotensin II infusion, and in situ hybridization showed the co-localization of these mRNAs. Tubular cells that had increased PDGF-B mRNA expression were positive for lipid deposition and also for cellular proliferation, which was indicated by the presence of proliferating cell nuclear antigen. By contrast, in the kidneys of angiotensin II-infused rats, apoptosis occurred in tubular cells that contained deposits of iron but not lipids. The deposition of lipids and upregulation of PDGF-B, PDGF-D, and PDGFR-b induced by administration of angiotensin II were all suppressed by the selective angiotensin II type 1 (AT 1 ) receptor antagonist losartan, but not by the nonspecific vasodilator hydralazine. The findings that lipid accumulation, upregulation of PDGF-B, PDGF-D, and PDGFR-b, and cellular proliferation were topologically associated and regulated in an AT 1 receptor-dependent manner in the kidney of angiotensin II-infused rats suggests that these phenomena are related.
Lipids may accumulate in nonadipose tissues such as the arterial wall, heart, and liver, in certain disease conditions, [1] [2] [3] and the accumulated lipids may exacerbate morphological and functional damage in these tissues. 2, 4 Recent studies have shown that deposition of lipids occurs also in the kidney of the animal models of diabetes, obesity, and aging. [5] [6] [7] [8] Accumulation of triglycerides in the kidney is reported in animal models of unilateral ureteral obstruction, 9 glycerol-induced rhabdomyolysis, and renal ischemia and subsequent reperfusion. 10 The finding that increasing renal triglyceride content by transuding exogenous sterol regulatory elementbinding protein (SREBP)-1 resulted in upregulation of transforming growth factor (TGF)-b1 and an increase in proteinuria, 5 suggests that, besides being a marker of tissue damage, lipid accumulation in renal cells may be involved in the development of renal injury.
TGF-b and platelet-derived growth factor (PDGF) 11 are thought to play key roles in renal damage in some disorders. 11, 12 Inhibition of angiotensin-converting enzyme activity and blockade of the angiotensin II type 1 (AT 1 ) receptor reduce the expression of these genes. [13] [14] [15] [16] [17] whereas administration of angiotensin II upregulates their expression. 18, 19 Thus, activation of the renin-angiotensin system or increased local concentration of angiotensin II may enhance renal damage by the upregulation of these fibroproliferative genes in cortical tubular epithelial cells. 20 We previously demonstrated that long-term administration of angiotensin II caused marked depositions of iron 21 and lipid 22 in the rat kidney. Histological analysis showed that expression of TGF-b and production of superoxides were both increased in renal cells with lipid deposition. We therefore hypothesized that expression of PDGF and its receptor system might be upregulated in the lipid-positive cells in the kidneys of angiotensin II-infused animals. In this paper, we investigate whether PDGF-B, PDGF-D, and PDGF receptor-b (PDGFR-b) are induced in the kidneys of angiotensin II-infused rats, and determine the localization of the receptor and ligands by in situ hybridization.
Materials and methods

Animal Models
This study was performed in accordance with the guidelines for animal experimentation approved by the Animal Center for Biomedical Research, Faculty of Medicine, University of Tokyo. Angiotensin IIinduced hypertension was induced in male Sprague-Dawley rats (250-300 g) by subcutaneous implantation of an osmotic minipump (Alzet model 2001; Alza Pharmaceutical, Palo Alto, CA, USA) as described previously. 23 In brief, Val 5 -Angiotensin II and norepinephrine (Sigma) were infused at doses of 0.7 mg/kg/day (B140 ng/min) and 2.8 mg/kg/day, respectively, for 7 days by subcutaneously implanted osmotic minipumps (Alza). These treatments exerted hypertensive effects (angiotensin II, 19275 mmHg (n ¼ 12); norepinephrine, 19274 mmHg (n ¼ 12), Po0.01 vs control rats, 13173 mmHg (n ¼ 6)). Systolic blood pressure was measured in conscious rats by tail-cuff plethysmography (Ueda Seisakusyo). In some experiments, the selective AT 1 receptor antagonist losartan (25 mg/kg/day) or the nonspecific vasodilator hydralazine (15 mg/kg/day) (Sigma) were given in the drinking water, 2 days prior to pump implantation and throughout the angiotensin II infusion (angiotensin II þ losartan, 12675 mmHg (n ¼ 7); angiotensin II þ hydralazine 12673 mmHg (n ¼ 7)).
Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Quantitative RT-PCR was performed as described previously with LightCycler (Roche Diagnostics, Basel, Switzerland). 24 Forward and reverse primers 
Western Blot Analysis
Western blot analysis for SREBP-1 was performed as described previously. 22, 25 In Situ Hybridization and Immunohistochemistry In situ hybridization was performed as described previously. 26 Immunohistochemistry was performed as described previously. 25 Primary antibodies against PDGFR-b (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and proliferating cell nuclear antigen (PCNA, DAKO Japan, Kyoto, Japan) were used at a dilution of 1/200.
Deposition of Lipid and Iron
Oil red O staining was performed on 3 mm sections of unfixed, freshly frozen kidney samples. For semiquantification of the lipid deposition, images of each specimen stained with oil red O were taken with an Olympus BX51 microscope and a DP12 digital camera system (Olympus, Tokyo, Japan). Five images taken in the cortical regions of each sample were analyzed. The ratio of the areas of lipid deposition to the total tissue region area was calculated by using the image analysis software (9) (6) (7) (10) (6) (6) (6) (6) (6) (6) (9) (6) (7) 
Determination of Apoptosis
Frozen sections (3 mm thick) were fixed with in 4% paraformaldehyde and examined by the terminal deoxynucleotidyl transferase (TdT)-mediated dUTPbiotin nick end labeling (TUNEL) technique as described previously. 27 
Statistical Analysis
Data are expressed as the mean7s.e.m. We used ANOVA followed by a multiple comparison test to compare raw data, before expressing the results as a percentage of the control value using the statistical analysis software StatView version 5.0 (SAS Institute, NC, USA). A value of Po0.05 was considered to be statistically significant.
Results
Expression and Localization of PDGF-B, PDGFR-b, and PDGF-D mRNA
In situ hybridization revealed that the expression of PDGF-B mRNA was increased in the kidneys of angiotensin II-infused rats as compared to untreated controls (Figure 1a (Figure 1o and p) . Quantitative RT-PCR showed that angiotensin II infusion significantly increased mRNA expression of PDGF-B, PDGFR-b, and PDGF-D, which could be suppressed by the AT 1 receptor blockade by losartan, but not by the vasodilator hydralazine. Norepinephrine, which exerted hypertensive effects that were comparable to angiotensin II, did not increase the expression of mRNA in expression of either PDGF-B, PDGFR-b, or PDGF-D (Figure 1q-s) .
Localization of PDGF-B, Iron, and Lipid Deposits
Staining of serially cut specimens showed that majority of tubular cells that expressed increased levels of PDGFR-b and PDGF-B mRNA expression did not contain iron deposits (Figure 2a-c) . Immunohistochemistry showed that levels of PDGFR-b protein were higher after infusion of angiotensin II, but cells with increased PDGFR-b protein expression were again found to be negative for iron deposition (Figure 2d-f) . By contrast, staining of serial frozen sections showed that PDGF-B mRNA expression was intense in the tubular epithelial (Figure 2g and h) and vascular wall cells (Figure 2i and j) that were positive for lipid deposits. PCNA was found to be positive in the tubular cells that expressed increased levels of PDGF-B mRNA (Figure 2k and l) that was in accordance with previous report. 
Effects of Various Pressor and Antipressor Agents on Lipid Deposition and Regulation of Expression of Lipid Metabolism-Related Genes
We next determined the effects of the pressor and antipressor agents, which had been used to investigate the regulation of PDGF-B, PDGF-D, and PDGFR-b (Figure 1 ) on angiotensin II-induced accumulation of lipids and upregulation lipid metabolism-related genes. Angiotensin II-induced lipid accumulation could be suppressed by losartan, but not by hydralazine (Figure 4a-d) . Administration of norepinephrine did not result in lipid deposition in the kidney (Figure 4e ). 
2% (NS vs control).
The angiotensin II-induced upregulation of protein expression of SREBP-1 (Figure 4f and g ) was inhibited by losartan, but not by hydralazine. Angiotensin II-induced upregulation of mRNA expression of FAS and LDL-R were also suppressed by losartan, but not by hydralazine (Figure 4h and i) . Norepinephrine treatment did not increase expression of SREBP-1 (data not shown), FAS, or LDL-R (Figure 4h and i) . Expression of HMG-CoA-R was not significantly altered by any of these treatments ( Figure 4J ).
Discussion
In the present study, we demonstrated that expression of PDGF-B, PDGF-D, and PDGFR-b mRNA was increased in the kidney of rats that were made hypertensive by angiotensin II but not by norepinephrine. In situ hybridization showed the colocalization of mRNA expression of these genes. Histological analysis showed that only a small fraction of PDGF-B mRNA signals co-localized with iron deposits, but a substantial fraction co-localized with lipid droplets. In the kidney of angiotensin IIinfused rat, cells with increased PDGF-B mRNA expression and in those with lipid accumulation were also PCNA positive. These data collectively suggest that lipid deposition, PDGF, and renal cell proliferation may be related in the kidney of the angiotensin II-induced hypertensive rat. It has been previously shown by Johnson et al 19 that administration of angiotensin II induces PDGF-B expression in the renal tubular cells. In the present study, we showed that angiotensin II infusion induced upregulation of PDGF-B and PDGFR-b mRNA in the kidney, and this could be suppressed by the AT 1 receptor antagonist losartan, but not by the vasodilator hydralazine. These findings suggest that angiotensin II-upregulated expression of these genes by an AT 1 receptordependent mechanism, an idea that is further supported by our finding that norepinephrine did not cause upregulation of these genes. We also demonstrated that mRNA expression of PDGF-D, a newly discovered member of PDGF family that mediates renal cell proliferation, also showed similar pattern of regulation by pressor and antipressor agents. The distribution pattern of Angiotensin II, PDGF, and lipid deposition N Ishizaka et al PDGF-D mRNA was reported to be closely similar to that of PDGFR-b in murine renal fibrosis induced by unilateral ureteral obstruction. 29 In the current study, we showed the co-localization of mRNA expression of PDGF-D, PDGF-B, and PDGFR-b (Figure 1m-p) in the kidney of the angiotensin IIinduced rat.
We previously found that long-term administration of angiotensin II resulted in a marked deposition of iron 21 and lipid 22 in the kidney. Although several previous studies have shown deposition of iron 30 and lipid 5, 6, 8, 31 in other animal models, the physiological importance of the renal iron and lipid deposition has not been well established. Sun et al 5 have recently reported that introducing exogenous SREBP-1 gene to the kidney resulted not only in the renal lipid deposition, but also in increased albuminuria and upregulation of TGF-b1 expression, suggesting that alterations in lipid metabolism in the kidney may have a role in renal function and regulation of gene expression. We also found the topological association between TGF-b1 mRNA expression and lipid deposition, but not iron deposition, in the kidney of angiotensin II-infused rat. 18, 22 As both PDGF and TGF-b may to play a modulatory role in the progression of renal injury in certain diseased condition, 32 these previous findings lead us to investigate the regulation of PDGF-B, as well as PDGF-D and PGDFR-b, and their histological localization in the kidney of angiotensin II-infused rats.
In a previous study, we showed that angiotensin II infusion induced renal cellular proliferation, which could be suppressed by losartan, but not hydralazine. 27 In the current study, in addition to the topological association between PDGF-B, PCNA, and lipid deposition, mRNA expression of PDGF-B/PDGF-D (Figure 1q and s) and area of lipid deposition (Figure 4a -e) were regulated by an AT 1 receptor-dependent and pressor-independent manner. As PDGF-D, as well as PDGF-B, may promote renal cellular proliferation when upregulated, 33 these finding might suggest that altered lipid homeostasis is an upstream phenomenon in the PDGF-B/ PDGF-D-induced renal cellular proliferation in the kidneys of angiotensin II-treated rats. This scenario is supported by the finding by a previous in vitro study that showed that simulation of the renal cells with triglyceride-rich lipoproteins increased the secretion of PDGF and TGF-b from these cells and promote their proliferation. 34 In contrast to proliferation, TUNEL-positive apoptosis was found in the cells with iron deposition, but not in those with lipid deposition. Previous studies showed that heme or iron may exacerbate renal cell apoptosis, presumably, in part, by iron-induced oxidative stress. 35, 36 Again, a causal or resultant relationship between iron deposition and renal cell apoptosis could not be determined in the current study; it will be pursued in future studies.
Accumulation of lipid droplets in glomerular and renal tubular cells has been reported in an animal model of diabetes, 5, 8 which is postulated to modulate the expression of fibrogenesis-related genes and proteinuria. 5 Importantly, analysis of renal biopsy specimens from patients with kidney diseases showed that deposition of lipid, 37 as well as iron, 38 may not be uncommon. The pathophysiological roles of lipid deposition in the kidney and its possible association with the renin-angiotensin system need further investigation.
In conclusion, long-term administration of angiotensin II increased the expression of PDGF-B, PDGF-D, and PDGFR-b mRNA in the rat kidney. It was shown histologically that cells with increased PDGF-B mRNA expression contained lipid deposits. In addition, cellular proliferation was observed in lipid-positive cells and PDGF-B-positive cells. These data collectively suggest the possible relationship between altered lipid metabolism, upregulation of PDGF-B/PDGF-D, and cellular proliferation in the kidney of hypertensive animal models of angiotensin II infusion.
